While discussing Amarin, will the company find a partner to help launch Vascepa, or perhaps a buyer?
New drug launches to watch in the last four months of 2012: Medivation's Xtandi, Ironwood Pharmaceuticals' (IRWD) Linzess, Onyx Pharma's (ONXX) Kyprolis and Vivus' (VVUS) Qsymia.
I can't mention Vivus and ignore Arena Pharmaceuticals (ARNA), which is expected to receive DEA scheduling for Belviq before the end of the year so that the obesity drug can be launched early in 2013.
Will Peregrine Pharmaceuticals (PPHM) sign a partner before starting the bavituximab phase III lung cancer study at year's end, as promised?
Same goes for YM BioSciences (YMI): Where is the promised partner to co-develop the myelobfibrosis drug CYT387? Can Idenix Pharmaceuticals (IDIX) gather enough safety data to convince FDA to lift the clinical hold on its hepatitis C drugs? Will Achillion Pharmaceuticals (ACHN), which like Idenix is seeking partners or buyers for its hepatitis C drugs, finally change its Facebook status to "In a Relationship?" --Written by Adam Feuerstein in Boston.>To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: tips@thestreet.com. Follow TheStreet on Twitter and become a fan on Facebook.
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
